Individualized tcr and antigen cancer treatment
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
96
NCT07145450
Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jul 3, 2025
Completion: Jul 31, 2030
Loading map...